Salient ENT

Chronic rhinosinusitis (CRS), recurrent and persistent inflammation of the nasal sinuses, is a chronic condition that affects almost one in eight Americans, yet few options exist for reliable treatment of the disease’s debilitating symptoms. Patients with CRS find it difficult to lead a normal life while faced with headaches, insomnia, painful facial pressure, and persistent infections. While almost every CRS sufferer uses sinus rinses daily, this regimen is ineffective for patients with the most advanced forms of the disease. As a result, sufferers must try increasingly expensive and invasive treatments, ultimately sending over half a million people to undergo functional endoscopic sinus surgery (FESS) every year. However, the procedure only marginally increases the efficacy of saline rinses and will have to be revised in a third of patients within three to six years. Overall, this process is costly for both the individual and the healthcare system, as patients spend thousands of dollars on over the counter treatments, incur $8.6 billion in direct surgical costs, and cause $24 billion in lost economic output annually. In an effort to help patients who have received FESS better rinse their sinuses, competitors have developed treatments such as balloon sinuplasty and nasal stents that attempt to open sinus ostia and maintain sinus patency. However, none of these options ensure reliable sinus access or facilitate direct sinus irrigation. Salient ENT addresses these shortcomings with the Hana Catheter (Figure 1), a product designed to bring saline and other therapeutic fluids directly to inflamed sinus tissues. The Hana Catheter system includes a novel, low profile nasal device and an external rinse bottle that interfaces with the internal catheter. By providing a conduit through constricted sinus openings, the Hana Catheter can increase fluid delivery up to eight-fold over the standard of care. This solution provides a more targeted treatment delivery option for CRS patients, which can minimize recurrent symptoms and reduce the need for surgical revision procedures.